menu
    • menu
    [{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"ImmunoGenesis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ ImmunoGenesis","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ ImmunoGenesis"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Agenus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoGenesis \/ Agenus","highestDevelopmentStatusID":"7","companyTruncated":"ImmunoGenesis \/ Agenus"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoGenesis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunoGenesis \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Evofosfamide

    Menu

    Evofosfamide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ImmunoGenesis

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            ImmunoGenesis

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evofosfamide,Balstilimab,Zalifrelimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ImmunoGenesis Doses First Patient in IMGS-101 Combo Trial for Solid Tumors

                            Details : IMGS-101 (evofosfamide) is a DNA inhibitor, which is being evaluated for the treatment of rmetastatic castration-resistant prostate cancer, pancreatic, & HPV(-) head & neck tumors.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 06, 2025

                            Lead Product(s) : Evofosfamide,Balstilimab,Zalifrelimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University Health Network, Toronto

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            University Health Network, Toronto

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : ImmunoGenesis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Cast...

                            Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 20, 2025

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : ImmunoGenesis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ImmunoGenesis

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            ImmunoGenesis

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Agenus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

                            Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 20, 2025

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Agenus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Molecular Templates

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Molecular Templates

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

                            Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 31, 2017

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sarcoma Alliance for Research through Collaboration

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Sarcoma Alliance for Research through Collaboration

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Molecular Templates

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SARC021C: A Continuation Study of TH-CR-406/SARC021

                            Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in clinical studies for the treatment of Sarcoma.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 18, 2016

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Molecular Templates

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Maastricht Radiation Oncology

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Maastricht Radiation Oncology

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Molecular Templates | Zuyderland Medical Centre

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.

                            Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Esophageal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            November 06, 2015

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Molecular Templates | Zuyderland Medical Centre

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Seoul National University Hospital

                            South Korea arrow
                            The MedTech Conference
                            Not Confirmed

                            Seoul National University Hospital

                            South Korea arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Molecular Templates

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer

                            Details : TH-302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Biliary Tract Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            May 05, 2015

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Molecular Templates

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Grupo Espanol de Tumores Neuroendocrinos

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Grupo Espanol de Tumores Neuroendocrinos

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Molecular Templates | Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pan...

                            Details : TH-302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuroendocrine Tumors.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 30, 2015

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Molecular Templates | Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Merck Group

                            Germany arrow
                            The MedTech Conference
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Molecular Templates

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

                            Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sarcoma.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            October 02, 2014

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Molecular Templates

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ImmunoGenesis

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            ImmunoGenesis

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : EMD Serono

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Ca...

                            Details : TH-302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 21, 2014

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : EMD Serono

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth